Secondary prevention strategies in ischemic stroke: Identification and optimal management of modifiable risk factors

Mayo Clinic Proceedings

Volumn 79, Issue 10, 2004, Pages 1330-1340

  Flemming, Kelly D ^a   Brown Jr , Robert D ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CHLORTALIDONE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTRADIOL; ESTROGEN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; PYRIDOXINE; RAMIPRIL; SIMVASTATIN; THROMBIN INHIBITOR; WARFARIN;

ALCOHOL CONSUMPTION; BLEEDING; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; METABOLIC SYNDROME X; MYOPATHY; NURSE BASED CASE MANAGEMENT SYSTEM; OBESITY; PATIENT CARE; PATIENT EDUCATION; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SLEEP APNEA SYNDROME; SMOKING; THROMBOEMBOLISM;

EID: 4644241899     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.10.1330     Document Type: Conference Paper

References (127)

1. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999; 354:1457-1463.
2. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112-1120.
3. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med. 1995;333:1392-1400.
4. Feinberg WM. Primary and secondary stroke prevention. Curr Opin Neurol. 1996;9:46-52.
5. Holloway RG, Benesch C, Rush SR. Stroke prevention: narrowing the evidence-practice gap. Neurology. 2000;54:1899-1906.
6. Kalra L, Perez I, Melbourn A. Stroke risk management: changes in mainstream practice. Stroke. 1998;29:53-57.
7. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280-299.
8. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
10. Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 2000;54:790-796.
11. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421-1428.
12. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
13. American Diabetes Association. Clinical practice recommendations 1998. Diabetes Care. 1998;21 (suppl 1):S1-S90.
14. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH, Anticoagulation Guidelines Task Force. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmocother. 1997;31:604-615.
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
16. Hankey GJ. One year after CAPRIE, IST and ESPS 2: any changes in concepts? Cerebrovasc Dis. 1998;8(suppl 5):1-7.
17. Easton JD. What have we learned from recent antiplatelet trials? Neurology. 1998;51(3, suppl 3):S36-S38.
18. Gueyffier F, Boissel JP, Boutitie F, et al, INDANA Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke. 1997;28:2557-2562.
19. PROGRESS Management Committee. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens. 1999;17:1647-1655.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
21. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
22. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Investigators. Benefit of carotid endarterectomy for patients with high-grade stenosis of the internal carotid artery. Stroke. 1991;22:816-817.
23. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
24. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ. 1997;314:1151-1159.
25. Wilterdink JL, Furie KL, Easton JD. Cardiac evaluation of stroke patients. Neurology. 1998;51(3, suppl 3):S23-S26.
26. Brown RD Jr, Sejvar JJ, Vernino SA, Petty GW, Sicks JD, O'Fallon WM. Myocardial infarction following cerebral infarction: frequency, timing, and predictors in a population-based study [abstract]. Neurology. 2000; 54(suppl 3):A155. Abstract S27.001.
27. Vemino S, Brown RD Jr, Sejvar JJ, Sicks JD, Petty GW, O'Fallon WM. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke. 2003;34:1828-1832.
28. Aben I, Verhey F, Strik J, Lousberg R, Lodder J, Honig A. A comparative study into the one year cumulative incidence of depression after stroke and myocardial infarction. J Neurol Neurosurg Psychiatry. 2003;74:581-585.
29. Narushima K, Robinson RG. Stroke-related depression. Curr. Atheroscler Rep. 2002;4:296-303.
30. Joseph LN, Babikian VL, Allen NC, Winter MR. Risk factor modification in stroke prevention: the experience of a stroke clinic. Stroke. 1999;30:16-20.
31. Gordon DL, Cobb AB, McIlwain JS, et al. Cooperative stroke management project by a peer-review organization. J Stroke Cerebrovasc Dis. 1996;6:45-53.
32. Goldstein LB, Hey LA, Laney R. North Carolina stroke prevention and treatment facilities survey: statewide availability of programs and services. Stroke. 2000;31:66-70.
33. Pancioli AM, Broderick J, Kothari R, et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 1998;279:1288-1292.
34. Travis LH, Flemming KD, Brown RD Jr, Meissner I, McClelland RL, Weigand SD. Awareness of stroke risk factors, symptoms, and treatment is poor in people at highest risk. J Stroke Cerebrovasc Dis. 2003;12:221-227.
35. Becker K, Fruin M, Gooding T, Tirschwell D, Love P, Mankowski T. Community-based education improves stroke knowledge. Cerebrovasc Dis. 2001;11:34-43.
36. Rankin SH, Stallings KD. Patient Education: Principles and Practice. Philadelphia, Pa: Lippincott; 2001:280-281.
37. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York, NY: Guilford Press; 1991.
38. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819-822.
39. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
40. DeBusk RF. MULTIFIT: a new approach to risk factor modification. Cardiol Clin. 1996;14:143-157.
41. Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart. 1998;80:447-452.
42. Allison TG, Farkouh ME, Smars PA, et al. Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a chest pain evaluation in the emergency room [CHEER] substudy). Am J Cardiol. 2000;86:133-138.
43. Appel LJ, Champagne CM, Harsha DW, et al, Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093.
44. Elley CR, Kerse N, Arroll B, Robinson E. Effectiveness of counselling patients on physical activity in general practice: cluster randomised controlled trial. BMJ. 2003;326:793-796.
45. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
46. Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003;289:2560-2572.
47. Chobanian AV, Bakris GL, Black HR, et al, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003;289:2560-2572.
48. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
49. Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465-471.
50. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
51. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [published corrections appear in Lancet. 2001;358:1556 and 2002;359:2120]. Lancet. 2001;358:1033-1041.
52. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [published corrections appear in Lancet. 2001;358:1556 and 2002;359:2120]. Lancet. 2001;358:1033-1041.
53. Lonn E, Yusuf S, Dzavik V, et al, SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
54. Dahlof B, Devereux RB, Kjedldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
55. ALLHAT Officers and Coordinators for the Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [published corrections appear in JAMA. 2003;289:178 and 2004;291: 2196]. JAMA. 2002;288:2981-2997.
56. ALLHAT Officers and Coordinators for the Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [published corrections appear in JAMA. 2003;289:178 and 2004;291: 2196]. JAMA. 2002;288:2981-2997.
57. Brenner BM, Cooper ME, de Zeeuw D, et al, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
58. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy [published correction appears in N Engl J Med. 1993;330:152]. N Engl J Med. 1993;329:1456-1462.
59. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy [published correction appears in N Engl J Med. 1993;330:152]. N Engl J Med. 1993;329:1456-1462.
60. Bosch J, Yusuf S, Pogue J, et al, HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:699-702.
61. Davis SM, Donnan GA. Blood pressure reduction and ace inhibition in secondary stroke prevention: mechanism uncertain [editorial]. Stroke. 2003;34:1335-1336.
62. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910.
63. O'Leary DH, Polak JF, Kronmal RA, et al, CHS Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. Stroke. 1992;23:1752-1760.
64. Fine-Edelstein JS, Wolf PA, O'Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology. 1994;44: 1046-1050.
65. Kargman DE, Tuck C, Berglund LF, et al. Elevated high-density lipoprotein levels are more important in atherosclerotic ischemic stroke subtypes: the Northern Manhattan Stroke Study [abstract]. Ann Neurol. 1998;44:442-443. Abstract M8.
66. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes [published correction appears in BMJ. 1991;303: 968]. BMJ. 1991; 303:605-609.
67. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes [published correction appears in BMJ. 1991;303: 968]. BMJ. 1991; 303:605-609.
68. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:317-326.
69. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
70. Hodis HN. Reversibility of atherosclerosis-evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. J Cardiovasc Pharmacol. 1995;25(suppl 4):S25-S31.
71. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) [published correction appears in Am J Cardiol. 1995;75:862]. Am J Cardiol. 1995;75:455-459.
72. Furberg CD, Adams HP Jr, Applegate WB, et al, Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
73. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101:627-634.
74. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
75. Nissen SE, Tuzcu EM, Schoenhagen P, et al, REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
76. Cannon CP, Braunwald E, McCabe CH, et al, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
77. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
78. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
79. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000.
80. Bonita R, Duncan J, Truelsen T, Jackson RT, Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control. Summer 1999;8:156-160.
81. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger A. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA. 1988;259: 1025-1029.
82. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269:232-236.
83. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(1, suppl): 194S-206S.
84. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
85. Olsson S, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
86. Practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:671-673.
87. Castaldo JE. Indications for treatment of asymptomatic carotid stenosis. Neurosurg Clin N Am. 2000;11:247-264.
88. Hobson RW II, Weiss D, Fields WS, et al, Veterans Affairs Cooperative Study Group. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. N Engl J Med. 1993;328:221-227.
89. Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Clin Proc. 1992;67:513-518.
90. CASANOVA Study Group. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. Stroke. 1991;22:1229-1235.
91. Halliday A, Mansfield A, Marro J, et al, MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatalstrokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363:1491-1502.
92. Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation. 1998;97:501-509.
93. Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost. 1997;78:527-531.
94. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
95. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
96. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation. 2004;109:42-46.
97. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109: 551-556.
98. Haheim LL, Holme I, Hjermann I, Leren P. Risk factors of stroke incidence and mortality: a 12-year follow-up of the Oslo Study. Stroke. 1993; 24:1484-1489.
99. Fletcher GF. Exercise in the prevention of stroke. Health Rep. 1994; 6:106-110.
100. Abbott RD, Rodriguez BL, Burchfiel CM, Carb JD. Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program. Am J Epidemiol. 1994;139:881-893.
101. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Kannel WB. Physical activity and stroke risk: the Framingham Study [published correction appears in Am J Epidemiol. 1995;141:178]. Am J Epidemiol. 1994;140:608-620.
102. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Kannel WB. Physical activity and stroke risk: the Framingham Study [published correction appears in Am J Epidemiol. 1995;141:178]. Am J Epidemiol. 1994;140:608-620.
103. Lee CD, Blair SN. Cardiorespiratory fitness and stroke mortality in men. Med Sci Sports Exerc. 2002;34:592-595.
104. Lindenstrom E, Boysen G, Nyboe J. Lifestyle factors and risk of cerebrovascular disease in women: the Copenhagen City Heart Study. Stroke. 1993;24:1468-1472.
105. Gillum RF, Mussolino ME, Ingram DD. Physical activity and stroke incidence in women and men: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1996;143:860-869.
106. Sacco RL, Gan R, Boden-Albala B, et al. Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. Stroke. 1998;29:380-387.
107. Wannamethee G, Shaper AG. Physical activity and stroke in British middle aged men. BMJ. 1992;304:597-601.
108. Shinton R, Sagar G. Lifelong exercise and stroke [published correction appears in BMJ. 1993;307:706]. BMJ. 1993;307:231-234.
109. Shinton R, Sagar G. Lifelong exercise and stroke [published correction appears in BMJ. 1993;307:706]. BMJ. 1993;307:231-234.
110. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA. 1996;276: 241-246.
111. Pierson LM, Herbert WG, Norton HJ, et al. Effects of combined aerobic and resistance training versus aerobic training alone in cardiac rehabilitation. J Cardiopulm Rehabil. 2001;21:101-110.
112. Gordon NF, Gulanick M, Costa F, et al. Physical activity and exercise recommendations for stroke survivors: an American Heart Association scientific statement from the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention; the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and the Stroke Council. Circulation. 2004;109:2031-2041.
113. Pina IL, Balady GJ, Hanson P, Labovitz AJ, Madonna DW, Myers J. Guidelines for clinical exercise testing laboratories: a statement for healthcare professionals from the Committee on Exercise and Cardiac Rehabilitation, American Heart Association. Circulation. 1995;91:912-921.
114. Gill TM, DiPietro L, Krumholz HM. Role of exercise stress testing and safety monitoring, for older persons starting an exercise program. JAMA. 2000;284:342-349.
115. Malhotra A, White DP, Obstructive sleep apnoea. Lancet. 2002;360: 237-245.
116. Neau JP, Paquereau J, Meurice JC, Chavagnat JJ, Gil R. Stroke and sleep apnoea: cause or consequence? Sleep Med Rev. 2002;6:457-469.
117. Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
118. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med. 2002;113:543-548.
119. Hays J, Ockene JK, Brunner RL, et al, Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854.
120. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
121. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
122. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003;21:315-325.
123. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337:356]. N Engl J Med. 1997;336:973-979.
124. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337:356]. N Engl J Med. 1997;336:973-979.
125. Pearson TA, Menash GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
126. Ridker PM, Rifai N, Clearfield M, et al, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
127. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke. 2002;33:2459-2464.